目的 探讨血清转化生长因子β1(TGF-β1)、白细胞介素-17(IL-17)水平与急性肾盂肾炎患者头孢噻肟钠治疗预后的相关性。方法 选取2019年7月-2021年7月于我院采用孢噻肟钠治疗的急性肾盂肾炎患者60例,治疗2周后,观察患者预后情况并分为预后不良组与预后良好组,所有患者治疗前均接受血清TGF-β1、IL-17水平检测,分析血清TGF-β1、IL-17水平与急性肾盂肾炎患者头孢噻肟钠治疗预后的相关性。结果 60例急性肾盂肾炎患者头孢噻肟钠治疗预后不良8例(13.33%),预后良好52例(86.67%);经Logistic回归分析,结果显示,血清TGF-β1、IL-17水平与急性肾盂肾炎患者头孢噻污钠治疗预后不良相关(OR>1, P<0.05);绘制ROC曲线,结果显示,血清TGF-β1、IL-17水平单独及联合预测急性肾盂肾炎患者头孢噻肟钠治疗预后的AUC>0.8,具有一定预测价值,其中联合预测价值最高。结论 血清TGF-β1、IL-17水平与急性肾盂肾炎患者头孢噻肟钠治疗预后密切相关,临床可通过检测血清TGF-β1、IL-17水平预测急性肾盂肾炎患者预后情况。

Objective To investigate the correlation between serum transforming growth factor-β1 (TGF-β1), interleukin-17 (IL-17) and the prognosis of patients with acute pyelonephritis (AP) treated with cefotaxime sodium. Methods Totally 60 AP patients treated with cefotaxime sodium in our hospital from July 2019 to July 2021 were selected and divided into poor prognosis group and good prognosis group according to the prognosis of patients after two weeks of treatment. Patients in both groups received detection of serum TGF-β1 and IL-17 levels before treatment, and the correlation between serum TGF-β1 and IL-17 and the prognosis of AP patients treated with cefotaxime sodium was analyzed. Results Totally 60 AP patients were treated with cefotaxime sodium including 8 cases with poor prognosis (13.33%) and 52 cases with good prognosis (86.67%); Logistic regression analysis showed that high serum TGF-β1 and IL-17 levels were correlated with poor prognosis of patients (OR>1, P<0.05). Receiver operating characteristic curve (ROC curve) was drawn, and the results showed that the serum TGF-β1 and IL-17 levels predicted the prognosis of AP patients treated with cefotaxime sodium alone or in combination, with areas under curve (AUC)>0.8, which had certain prediction value, among which the joint prediction value was the highest. Conclusion The levels of serum TGF-β1 and IL-17 are closely related to the prognosis of AP patients treated with cefotaxime sodium, clinically, which may predict the prognosis of this patients.